445 related articles for article (PubMed ID: 24076968)
1. Extraordinary heterogeneity of virological outcomes in patients receiving highly antiretroviral therapy and monitored with the World Health Organization public health approach in sub-saharan Africa and southeast Asia.
Aghokeng AF; Monleau M; Eymard-Duvernay S; Dagnra A; Kania D; Ngo-Giang-Huong N; Toni TD; Touré-Kane C; Truong LX; Delaporte E; Chaix ML; Peeters M; Ayouba A;
Clin Infect Dis; 2014 Jan; 58(1):99-109. PubMed ID: 24076968
[TBL] [Abstract][Full Text] [Related]
2. Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies.
Hamers RL; Sigaloff KC; Wensing AM; Wallis CL; Kityo C; Siwale M; Mandaliya K; Ive P; Botes ME; Wellington M; Osibogun A; Stevens WS; Rinke de Wit TF; Schuurman R;
Clin Infect Dis; 2012 Jun; 54(11):1660-9. PubMed ID: 22474222
[TBL] [Abstract][Full Text] [Related]
3. Increasing rate of TAMs and etravirine resistance in HIV-1-infected adults between 12 and 24 months of treatment: the VOLTART cohort study in Côte d'Ivoire, West Africa.
Messou E; Chaix ML; Gabillard D; Yapo V; Toni TD; Minga A; Kouakou MG; Ouattara E; Rouzioux C; Danel C; Eholie SP; Anglaret X
J Acquir Immune Defic Syndr; 2013 Oct; 64(2):211-9. PubMed ID: 23797690
[TBL] [Abstract][Full Text] [Related]
4. Virological outcome and patterns of HIV-1 drug resistance in patients with 36 months' antiretroviral therapy experience in Cameroon.
Aghokeng AF; Kouanfack C; Eymard-Duvernay S; Butel C; Edoul GE; Laurent C; Koulla-Shiro S; Delaporte E; Mpoudi-Ngole E; Peeters M
J Int AIDS Soc; 2013 Jan; 16(1):18004. PubMed ID: 23374858
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of HIV-1 drug resistance among patients failing first-line ART in Monrovia, Liberia: a cross-sectional study.
Loubet P; Charpentier C; Visseaux B; Borbor A; Nuta C; Adu E; Chapplain JM; Baysah M; Tattevin P; Yazdanpanah Y; Descamps D
J Antimicrob Chemother; 2015; 70(6):1881-4. PubMed ID: 25698771
[TBL] [Abstract][Full Text] [Related]
6. Virological failure after 1 year of first-line ART is not associated with HIV minority drug resistance in rural Cameroon .
Zoufaly A; Jochum J; Hammerl R; Nassimi N; Raymond Y; Burchard GD; Schmiedel S; Drexler JF; Campbell NK; Taka N; Awasom C; Metzner KJ; van Lunzen J; Feldt T
J Antimicrob Chemother; 2015 Mar; 70(3):922-5. PubMed ID: 25428920
[TBL] [Abstract][Full Text] [Related]
7. Detecting virological failure in HIV-infected Tanzanian children.
Mgelea EM; Kisenge R; Aboud S
S Afr Med J; 2014 Jun; 104(10):696-9. PubMed ID: 25363057
[TBL] [Abstract][Full Text] [Related]
8. Secure antiretroviral therapy delivery in a resource-limited setting: streamlined to minimize drug resistance and expense.
Kitkungvan D; Apisarnthanarak A; Laowansiri P; Mundy LM
HIV Med; 2008 Oct; 9(8):636-41. PubMed ID: 18643857
[TBL] [Abstract][Full Text] [Related]
9. Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patients.
Soria A; Porten K; Fampou-Toundji JC; Galli L; Mougnutou R; Buard V; Kfutwah A; Vessière A; Rousset D; Teck R; Calmy A; Ciaffi L; Lazzarin A; Gianotti N
Antivir Ther; 2009; 14(3):339-47. PubMed ID: 19474468
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of a remote, decentralized health center-based HIV/AIDS antiretroviral program in Zambia, 2003 to 2007.
Elema R; Mills C; Yun O; Lokuge K; Ssonko C; Nyirongo N; Mtonga V; Zulu H; Tu D; Verputten M; O'Brien DP
J Int Assoc Physicians AIDS Care (Chic); 2009; 8(1):60-7. PubMed ID: 19211930
[TBL] [Abstract][Full Text] [Related]
11. Antiretroviral treatment outcome in HIV-1-infected patients routinely followed up in capital cities and remote areas of Senegal, Mali and Guinea-Conakry.
Diouara AA; Ndiaye HD; Guindo I; Bangoura N; Cissé M; Edmond T; Bougoudogo F; Mboup S; Peeters M; Ayouba A; Kane NC
J Int AIDS Soc; 2014; 17(1):19315. PubMed ID: 25527333
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of an affordable HIV-1 virological failure assay and antiretroviral drug resistance genotyping protocol.
Bronze M; Aitken SC; Wallis CL; Steegen K; Stuyver LJ; de Wit TF; Stevens W
J Virol Methods; 2013 Dec; 194(1-2):300-7. PubMed ID: 23994150
[TBL] [Abstract][Full Text] [Related]
13. Diagnosis of antiretroviral therapy failure in Malawi: poor performance of clinical and immunological WHO criteria.
van Oosterhout JJ; Brown L; Weigel R; Kumwenda JJ; Mzinganjira D; Saukila N; Mhango B; Hartung T; Phiri S; Hosseinipour MC
Trop Med Int Health; 2009 Aug; 14(8):856-61. PubMed ID: 19552661
[TBL] [Abstract][Full Text] [Related]
14. Short communication: three years follow-up of first-line antiretroviral therapy in cambodia: negative impact of prior antiretroviral treatment.
Ségéral O; Limsreng S; Nouhin J; Hak C; Ngin S; De Lavaissière M; Goujard C; Taburet AM; Nerrienet E; Delfraissy JF; Ouk V; Dulioust A
AIDS Res Hum Retroviruses; 2011 Jun; 27(6):597-603. PubMed ID: 21083413
[TBL] [Abstract][Full Text] [Related]
15. High efficacy of first-line ART in a West African cohort, assessed by dried blood spot virological and pharmacological measurements.
de Truchis P; Lê MP; Daou M; Madougou B; Nouhou Y; Moussa Saley S; Sani A; Adehossi E; Rouveix E; Saidou M; Peytavin G; Delaugerre C
J Antimicrob Chemother; 2016 Nov; 71(11):3222-3227. PubMed ID: 27439522
[TBL] [Abstract][Full Text] [Related]
16. Virological response and resistance among HIV-infected children receiving long-term antiretroviral therapy without virological monitoring in Uganda and Zimbabwe: Observational analyses within the randomised ARROW trial.
Szubert AJ; Prendergast AJ; Spyer MJ; Musiime V; Musoke P; Bwakura-Dangarembizi M; Nahirya-Ntege P; Thomason MJ; Ndashimye E; Nkanya I; Senfuma O; Mudenge B; Klein N; Gibb DM; Walker AS;
PLoS Med; 2017 Nov; 14(11):e1002432. PubMed ID: 29136032
[TBL] [Abstract][Full Text] [Related]
17. Viral suppression in adults, adolescents and children receiving antiretroviral therapy in Cameroon: adolescents at high risk of virological failure in the era of "test and treat".
Fokam J; Sosso SM; Yagai B; Billong SC; Djubgang Mbadie RE; Kamgaing Simo R; Edimo SV; Nka AD; Tiga Ayissi A; Yimga JF; Takou D; Moudourou S; Ngo Nemb M; Nfetam Elat JB; Santoro MM; Perno CF; Colizzi V; Ndjolo A
AIDS Res Ther; 2019 Nov; 16(1):36. PubMed ID: 31744517
[TBL] [Abstract][Full Text] [Related]
18. Prevalence and determinants of virological failure in HIV-infected children on antiretroviral therapy in rural Cameroon: a cross-sectional study.
Zoufaly A; Fillekes Q; Hammerl R; Nassimi N; Jochum J; Drexler JF; Awasom CN; Sunjoh F; Burchard GD; Burger DM; van Lunzen J; Feldt T
Antivir Ther; 2013; 18(5):681-90. PubMed ID: 23502762
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of treatment outcomes for patients on first-line regimens in US President's Emergency Plan for AIDS Relief (PEPFAR) clinics in Uganda: predictors of virological and immunological response from RV288 analyses.
Crawford KW; Wakabi S; Magala F; Kibuuka H; Liu M; Hamm TE
HIV Med; 2015 Feb; 16(2):95-104. PubMed ID: 25124078
[TBL] [Abstract][Full Text] [Related]
20. Association between medication possession ratio, virologic failure and drug resistance in HIV-1-infected adults on antiretroviral therapy in Côte d'Ivoire.
Messou E; Chaix ML; Gabillard D; Minga A; Losina E; Yapo V; Kouakou M; Danel C; Sloan C; Rouzioux C; Freedberg KA; Anglaret X
J Acquir Immune Defic Syndr; 2011 Apr; 56(4):356-64. PubMed ID: 21191309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
